Abstract
Abstract
Objective. Vagus nerve stimulation (VNS) is Food and Drug Administration-approved for epilepsy, depression, and obesity, and stroke rehabilitation; however, the morphological anatomy of the vagus nerve targeted by stimulatation is poorly understood. Here, we used microCT to quantify the fascicular structure and neuroanatomy of human cervical vagus nerves (cVNs). Approach. We collected eight mid-cVN specimens from five fixed cadavers (three left nerves, five right nerves). Analysis focused on the ‘surgical window’: 5 cm of length, centered around the VNS implant location. Tissue was stained with osmium tetroxide, embedded in paraffin, and imaged on a microCT scanner. We visualized and quantified the merging and splitting of fascicles, and report a morphometric analysis of fascicles: count, diameter, and area. Main results. In our sample of human cVNs, a fascicle split or merge event was observed every ∼560 µm (17.8 ± 6.1 events cm−1). Mean morphological outcomes included: fascicle count (6.6 ± 2.8 fascicles; range 1–15), fascicle diameter (514 ± 142 µm; range 147–1360 µm), and total cross-sectional fascicular area (1.32 ± 0.41 mm2; range 0.58–2.27 mm). Significance. The high degree of fascicular splitting and merging, along with wide range in key fascicular morphological parameters across humans may help to explain the clinical heterogeneity in patient responses to VNS. These data will enable modeling and experimental efforts to determine the clinical effect size of such variation. These data will also enable efforts to design improved VNS electrodes.
Funder
NIH SPARC
Veterans Administration Medical Center
Subject
Cellular and Molecular Neuroscience,Biomedical Engineering
Reference63 articles.
1. Expected budget impact and health outcomes of expanded use of vagus nerve stimulation therapy for drug-resistant epilepsy;Purser;Adv. Ther.,2018
2. Cyberonics announces 100,000th patient implant of VNS Therapy®,2012
3. FDA 2021 PMA approval P2100007 for vivistim system,2021
4. FDA 2015 PMA approval P130019 for maestro rechargeable system,2015
5. FDA 2005 PMA approval P970003 for VNS therapy system,2005
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献